Skip to main content
Premium Trial:

Request an Annual Quote

Osmetech Licenses Warfarin-Dosing SNP From Marshfield Clinic

NEW YORK (GenomeWeb News) - Osmetech said today it has exclusively licensed a molecular biomarker from Marshfield Clinic, a clinical and research facility in western Wisconsin, that it plans develop into a genetic test for determining appropriate warfarin doses.  
 
Osmetech plans to develop, manufacture, and sell a genetic test based on the biomarker. Osmetech CEO James White said the biomarker will be used on the company’s XT-8 platform.
 
"We are excited to add this new SNP to our warfarin product which is due to be submitted later this year to the US Food and Drug Administration,” White said in a statement. “The marker provides additional information to improve the dosage accuracy over any other product on the market."
 
Osmetech said it plans to market the product in the first half of 2008.
 
Financial terms of the agreement were not released.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.